Eptinezumab for prevention of Migraine

featured image
Interventions: Eptinezumab (ALD403)
Indications: Migraine
Therapeutic Areas: Neurology
Year: 2020

Eptinezumab is a medicinal product currently in clinical development for the prevention of migraine. A migraine is usually a moderate or severe headache felt as a throbbing pain on one side of the head. Many people also have symptoms such as nausea, vomiting and increased sensitivity to light or sound. Migraines may be with aura (specific warning signs just before the migraine begins, such as seeing flashing lights), although the most common type is without aura (no specific warning signs).

Eptinezumab is a drug, which potentially reduces the occurrence of migraine by blocking the CGRP ligand (a protein) from attaching to, and activating its receptor; a process thought to be involved in migraine. In clinical trials, eptinezumab appears effective and well tolerated in the prevention of migraine. If licenced, eptinezumab will offer an additional option for the preventative treatment of migraine with or without aura in adults.